John C F Clohisy1, Lawrence G Lenke2, Mostafa H El Dafrawy3, Rachel C Wolfe4, Elfaridah Frazier1, Michael P Kelly5. 1. Department of Orthopedic Surgery, Washington University School of Medicine, St. Louis, MO, USA. 2. Department of Orthopedic Surgery, Columbia University Medical Center, New York, NY, USA. 3. Department of Orthopedic Surgery, University of Chicago, Chicago, IL, USA. 4. Perioperative Services and Surgical Critical Care, Barnes-Jewish Hospital, St. Louis, MO, USA. 5. Rady Children's Hospital, University of California, 3020 Children's Way, San Diego, CA, 92123, USA. mkelly5@rchsd.org.
Abstract
BACKGROUND: Tranexamic acid (TXA) is an anti-fibrinolytic effective in reducing blood loss in orthopedic surgery. The appropriate dosing protocol for adult spinal deformity (ASD) surgery is not known. The purpose of this study was to evaluate two TXA protocols [low dose (L): 10 mg/kg bolus, 1 mg/kg/hr infusion; high dose (H): 50 mg/kg, 5 mg/kg/hr] in complex ASD surgery. METHODS: Inclusion criteria were ASD reconstructions with minimum 10 fusion levels or planned 3-column osteotomy (3CO). Standard demographic and surgical data were collected. Intraoperative estimated blood loss (EBL) was calculated by suction canisters minus irrigation plus estimated blood lost in sponges, estimated to the nearest 50 mL. Serious adverse events (SAE) were defined a priori as: venothromboembolic event (VTE), cardiac arrhythmia, myocardial infarction, renal dysfunction, and seizure. All SAE were recorded. Simple t tests compared EBL between groups. Mean EBL by total blood volume (TBV), transfusion volume, complications related to TXA were secondary outcomes. RESULTS: Sixty-two patients were enrolled and 52 patients completed the study; 25 were randomized to H and 27 to L. Demographic and surgical variables were not different between the two groups. EBL was not different between groups (H: 1596 ± 933 cc, L: 2046 ± 1105 cc, p = 0.12, 95% CI: - 1022 to 122 cc). EBL as a percentage of TBV was lower for the high-dose group (H: 29.5 ± 14.8%, L: 42.5 ± 26.2%, p = 0.03). Intraoperative transfusion volume (H: 961 ± 505 cc, L: 1105 ± 808 cc, p = 0.5) and post-operative transfusion volume (H: 513 ± 305 cc, L: 524 ± 245 cc, p = 0.9) were not different. SAE related to TXA were not different (p = 0.7) and occurred in 2 (8%) H and 3 (11%) L. There was one seizure (H), 2 VTE, and 2 arrhythmias. CONCLUSION: No differences in EBL, transfusion volume, nor SAE were observed between H and L dose TXA protocols. High dose was associated with decreased TBV loss (13%). Further prospective study, with pharmacologic analysis, is required to determine appropriate TXA dosage in ASD surgeries. LEVEL OF EVIDENCE: Therapeutic Level II. TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov (NCT02053363) February 3, 2014.
BACKGROUND: Tranexamic acid (TXA) is an anti-fibrinolytic effective in reducing blood loss in orthopedic surgery. The appropriate dosing protocol for adult spinal deformity (ASD) surgery is not known. The purpose of this study was to evaluate two TXA protocols [low dose (L): 10 mg/kg bolus, 1 mg/kg/hr infusion; high dose (H): 50 mg/kg, 5 mg/kg/hr] in complex ASD surgery. METHODS: Inclusion criteria were ASD reconstructions with minimum 10 fusion levels or planned 3-column osteotomy (3CO). Standard demographic and surgical data were collected. Intraoperative estimated blood loss (EBL) was calculated by suction canisters minus irrigation plus estimated blood lost in sponges, estimated to the nearest 50 mL. Serious adverse events (SAE) were defined a priori as: venothromboembolic event (VTE), cardiac arrhythmia, myocardial infarction, renal dysfunction, and seizure. All SAE were recorded. Simple t tests compared EBL between groups. Mean EBL by total blood volume (TBV), transfusion volume, complications related to TXA were secondary outcomes. RESULTS: Sixty-two patients were enrolled and 52 patients completed the study; 25 were randomized to H and 27 to L. Demographic and surgical variables were not different between the two groups. EBL was not different between groups (H: 1596 ± 933 cc, L: 2046 ± 1105 cc, p = 0.12, 95% CI: - 1022 to 122 cc). EBL as a percentage of TBV was lower for the high-dose group (H: 29.5 ± 14.8%, L: 42.5 ± 26.2%, p = 0.03). Intraoperative transfusion volume (H: 961 ± 505 cc, L: 1105 ± 808 cc, p = 0.5) and post-operative transfusion volume (H: 513 ± 305 cc, L: 524 ± 245 cc, p = 0.9) were not different. SAE related to TXA were not different (p = 0.7) and occurred in 2 (8%) H and 3 (11%) L. There was one seizure (H), 2 VTE, and 2 arrhythmias. CONCLUSION: No differences in EBL, transfusion volume, nor SAE were observed between H and L dose TXA protocols. High dose was associated with decreased TBV loss (13%). Further prospective study, with pharmacologic analysis, is required to determine appropriate TXA dosage in ASD surgeries. LEVEL OF EVIDENCE: Therapeutic Level II. TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov (NCT02053363) February 3, 2014.
Authors: Hossein Elgafy; Richard J Bransford; Robert A McGuire; Joseph R Dettori; Dena Fischer Journal: Spine (Phila Pa 1976) Date: 2010-04-20 Impact factor: 3.468
Authors: Gbolahan O Okubadejo; Keith H Bridwell; Lawrence G Lenke; Jacob M Buchowski; David D Fang; Christine R Baldus; Carl H Nielsen; Chris C Lee Journal: Spine (Phila Pa 1976) Date: 2007-09-15 Impact factor: 3.468
Authors: Kushagra Verma; Thomas Errico; Chris Diefenbach; Christian Hoelscher; Austin Peters; Joseph Dryer; Tessa Huncke; Kirstin Boenigk; Baron S Lonner Journal: J Bone Joint Surg Am Date: 2014-05-21 Impact factor: 5.284
Authors: Sean M Berenholtz; Julius Cuong Pham; Elizabeth Garrett-Mayer; Christine W Atchison; John P Kostuik; David B Cohen; Shantanu Nundy; Todd Dorman; Paul M Ness; Michael J Klag; Peter J Pronovost; Khaled M Kebaish Journal: Spine (Phila Pa 1976) Date: 2009-09-01 Impact factor: 3.468